PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 3,081 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 3,081 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $213,698.16. Following the completion of the transaction, the vice president owned 108,231 shares in the company, valued at approximately $7,506,902.16. The trade was a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, February 17th, Mark Elliott Boulding sold 2,813 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.29, for a total value of $194,912.77.
• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total value of $180,330.02.
• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total transaction of $171,196.30.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT traded up $0.97 during midday trading on Thursday, hitting $69.90. 976,090 shares of the company’s stock were exchanged, compared to its average volume of 1,253,063. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The company has a market cap of $5.61 billion, a PE ratio of 8.17 and a beta of 0.48. The stock has a 50 day moving average price of $75.12 and a 200-day moving average price of $67.76.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.30). The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. On average, analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UMB Bank n.a. bought a new stake in shares of PTC Therapeutics in the 4th quarter worth approximately $26,000. Smartleaf Asset Management LLC increased its position in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 236 shares during the last quarter. Optiver Holding B.V. increased its position in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the last quarter. Comerica Bank raised its stake in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares during the period. Finally, Salomon & Ludwin LLC purchased a new position in shares of PTC Therapeutics during the 4th quarter valued at $41,000.

Analyst Ratings Changes

PTCT has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group raised their price target on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Citigroup upped their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Barclays upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $68.00 to $119.00 in a research note on Tuesday, January 27th. Finally, TD Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Ten equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.